B7-1 (タンパク質 | 抗体 | cDNA クローン | ELISA キット)

All B7-1 reagents are produced in house and quality controlled, including 24 B7-1 Antibody, 52 B7-1 Gene, 10 B7-1 Lysate, 10 B7-1 Protein, 3 B7-1 qPCR. All B7-1 reagents are ready to use.

B7-1 Protein (10)

B7-1 Antibody (24)

B7-1 cDNA Clone (52)

NM_005191.3

クローニングベクター cDNA 製品

In lentiviral vector

NM_009855.2

クローニングベクター cDNA 製品

In lentiviral vector

NM_012926.1

クローニングベクター cDNA 製品

In lentiviral vector

NM_001042642.1

クローニングベクター cDNA 製品

In lentiviral vector

B7-1 Lysate (10)

B7-1 の背景知識

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD8, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD8 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 の参考文献

  • Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
  • Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
  • Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.